Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 6/20 | 0.61 |
| ▸ | EYA3 | Q99504 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9657351 | 0.83 | CYP2C19 (0.63) | CYP2C19EYA3CYP2C9THRATHRB | |
| SCHEMBL1398779 | 0.83 | CYP2C19 (0.63) | CYP2C19EYA3CYP2C9THRATHRB | |
| SCHEMBL4670295 | 0.81 | CYP2C19 (0.61) | CYP2C19EYA3CYP2C9THRATHRB | |
| SCHEMBL20441188 | 0.81 | CYP2C19 (0.61) | CYP2C19EYA3CYP2C9THRATHRB | |
| SCHEMBL25006551 | 0.80 | CYP2C19 (0.55) | CYP2C19EYA3POLBSMN1; SMN2CYP2C9 | |
| SCHEMBL28245008 | 0.80 | CYP2C19 (0.79) | CYP2C19EYA3CYP2C9THRATHRB | |
| SCHEMBL23604030 | 0.80 | CYP2C19 (0.59) | CYP2C19EYA3POLBCYP2C9THRA | |
| SCHEMBL15155615 | 0.79 | ALDH1A1 (0.54) | POLBSMN1; SMN2ALDH1A1GLAKDM4E | |
| SCHEMBL18018241 | 0.79 | CYP2C19 (0.61) | CYP2C19EYA3POLBSMN1; SMN2CYP2C9 | |
| SCHEMBL3263341 | 0.79 | CYP2C19 (0.58) | CYP2C19EYA3CYP2C9THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119403794-A | Novel derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-02-07 | — | — | CN | claimed |
| US-20240051949-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2024-02-15 | — | — | US | claimed |
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2023-12-07 | — | — | US | claimed |
| CN-106459030-B | Replace tropane derivatives | 东亚荣养株式会社 | 2019-01-29 | — | — | CN | claimed |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | disclosed |
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025224601-A1 | TRPM3 ANTAGONISTS FOR THE TREATMENT OF MIGRAINE AND PAIN | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-10-30 | — | — | WO | disclosed |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-09-02 | — | — | US | disclosed |
| WO-2025111414-A1 | TRPM3-MODULATING BENZOFURAN DERIVATIVES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-05-30 | — | — | WO | disclosed |
| CN-119403794-A | Novel derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-02-07 | — | — | CN | disclosed |
| US-20240336602-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2024-10-10 | — | — | US | disclosed |
| US-20240051949-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2024-02-15 | — | — | US | disclosed |
| EP-2545042-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012067663-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011112191-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011103063-A1 | THERAPEUTIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-08-25 | — | — | WO | disclosed |
| EP-2326633-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010030592-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-18 | — | — | WO | disclosed |
| EP-1948137-A2 | PHARMACEUTICAL FORMULATIONS CONTAINING 5-CYCLOPROPYL-2(4-FLUOROPHENYL)-6-(2-HYDROXYETHYL)(METHYLSULFONYL) AMINO-N-METHYL-1-BENZOFURAN-3-CARBOXAMIDE AND METHOD OF MAKING SAME | Wyeth a Corporation of the State of Delaware (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007059422-A2 | PHARMACEUTICAL FORMULATIONS CONTAINING 5-CYCLOPROPYL-2(4-FLUOROPHENYL)-6-[(2-HYDROXYETHYL)(METHYLSULFONYL) AMINO]-N-METHYL-1-BENZOFURAN-3-CARBOXAMIDE AND METHOD OF MAKING SAME | WYETH (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPV3, TRPM6, TRPM4 | CYP2C19 1846/4885EYA3 463/4885POLB 4670/4885 |
| US-20240051949-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM6, TRPM2 | CYP2C19 2795/4885EYA3 1007/4885POLB 4595/4885 |
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | FLT1, KDR, FLT4 | CYP2C19 166/4885EYA3 3188/4885POLB 1496/4885 |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | CYP2C19 2795/4885EYA3 1007/4885POLB 4595/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | CYP2C19 1615/4885EYA3 2728/4885POLB 3775/4885 |
| US-20240336602-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM6, TRPM2 | CYP2C19 2795/4885EYA3 1007/4885POLB 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.